Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy types 1 ...
BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results